Kolexia
Toullec Clemence Gastro-entérologie
Toullec Clemence
Gastro-entérologie
Institut Sainte Catherine
Avignon, France
105 Activités
573 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Carcinome épidermoïde Tumeurs colorectales Carcinome épidermoïde de la tête et du cou Instabilité des microsatellites Tumeurs de l'estomac Adénocarcinome Pseudokystes mucoïdes juxta-articulaires Tumeurs de l'anus

Collaborateurs

Voir plus
Mineur Laurent
Mineur Laurent
Centre Hospitalier de Apt, Apt, France
Calderon Benoit
Calderon Benoit
Imag En Coupes Avig Vaucl Site Ste Cat, Avignon, France
Kirscher Sylvie
Kirscher Sylvie
Institut Sainte Catherine, Avignon, France
Evesque Ludovic
Evesque Ludovic
Centre Antoine Lacassagne, Nice, France

Industries

Voir plus
Servier
30 collaboration(s)
Dernière en 2023
Amgen
19 collaboration(s)
Dernière en 2023
Sanofi
16 collaboration(s)
Dernière en 2023
Merck-Serono
11 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
HERIZON-GEA-01: A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
Essai Clinique (Jazz Pharmaceuticals)   04 mars 2024
Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   24 février 2024
SAFIR-ABC10: Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial
Essai Clinique (Taiho Oncology, Inc.)   15 novembre 2023
Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial.
JAMA oncology   19 octobre 2023
LOGICAN: Randomised Phase II Study Evaluating Trifluridine/Tipiracil Plus Oxaliplatin ± Nivolumab Versus FOLFOX ± Nivolumab in Patients With Gastric, Oesophagus or Gastroesophageal Junction Adenocarcinoma Locally Advanced, Recurrent or Metastatic, Ineligible for Triplet Chemotherapy
Essai Clinique (Servier)   12 octobre 2023
940P Salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck included in the phase II TOPNIVO trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
NIPISAFE: Analysis of the Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer: A GERCOR Open-label, Randomized, Non-comparative, Two-stage Phase II Trial (NIPISAFE).
Essai Clinique (BMS)   27 septembre 2023
Capecitabine/Mitomycin versus 5-Fluorouracil/Mitomycin in Combination with Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy for Anal Cancer.
Current oncology (Toronto, Ont.)   18 septembre 2023
OSCAR: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   16 août 2023
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO study.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association   07 mars 2023